<DOC>
	<DOC>NCT00656097</DOC>
	<brief_summary>The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) or placebo in combination with rabies vaccine in healthy adult subjects.</brief_summary>
	<brief_title>A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects free of obvious healthproblems or with stable condition Male or female subjects aged ≥19 to ≤65 years BMI between ≥18 and ≤30 kg/m2 Prior history of active or passive rabies immunization Clinically significant acute illness or infection within 2 weeks before first dosing based on the clinical judgment of the investigator History and/or family history of clinically significant immunodeficiency or autoimmune disease Any clinically significant history of known or suspected anaphylaxis or hypersensitivity reaction Chronic administration of immunosuppressants or other immunemodifying drugs within 6 months before the first dose of investigational medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Rabies post-exposure prophylaxis</keyword>
</DOC>